News

25 January 2017 – ACTION welcomes the signing of a licensing agreement between the Medicine Patent Pool (MPP) and the Johns Hopkins University, for an investigational tuberculosis (TB) treatment. The drug, sutezolid, holds significant promise for an effective new treatment for the world’s leading infectious killer. The signing, which took place, January 24 in Geneva, Switzerland, is the first licensing agreement for TB treatment announced by the MPP.

Drug-resistant TB cases up to 580,000. 13 October 2016 – New data released today by the World Health Organization shows that the tuberculosis (TB) epidemic is bigger than anyone had previously counted. There are now more cases, more deaths, and more drug resistance on record. This is the third year in a row that the estimate of total TB cases and deaths has been revised upward.

Further efforts to build on this investment are needed in the years ahead to put the diseases in the history books

July 19, 2016 — ACTION released a new report today that highlights the persistent need to coordinate an integrated response to the deadly duo of TB-HIV co-infections if additional progress is to be made against either disease.

Media advisory for a press conference on ACTION’s new TB-HIV research, "From Policy to Practice: How the TB-HIV Response is Working." ACTION, a global health advocacy partnership, will released a new report highlighting the persistent need to coordinate an integrated response to the "deadly duo" of TB-HIV co-infections if additional progress is to be made against either disease.

A groundbreaking report released today by the independent Review of Antimicrobial Resistance (AMR) in the U.K. presents a window of opportunity to transform the fight against TB, the world’s deadliest infectious disease.

Last fall, we learned a frightening truth: tuberculosis (TB) is now the leading infectious killer in the world, surpassing HIV/AIDS. But with distressing numbers came exciting solutions. If we seize them, a new set of opportunities could end TB in our generation.

As an ACTION partnership we are deeply saddened by the passing of Kraig Klaudt, one of ACTION’s founders and a deeply-dedicated, passionate, and visionary leader in the fight against TB and other diseases of poverty.